BIND Therapeutics

Quick facts

Phase 2 pipeline

• BIND-014 · Oncology
  BIND-014 is a targeted delivery system for small interfering RNA (siRNA) that targets the PD-1/PD-L1 pathway.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• BIND Therapeutics portfolio CI brief
• BIND Therapeutics pipeline updates RSS